Glaxo Sues Spectrum Pharma Over Imitrex Patent Challenge

Law360, New York (February 19, 2005, 12:00 AM EST) -- GlaxoSmithKline has sued specialty drug maker Spectrum Pharmaceuticals, Inc. over its challenge to Glaxo’s patent for the migraine injection treatment Imitrex.

Glaxo filed its lawsuit on Friday to prevent Spectrum from proceeding with the commercialization of its product. This action formally initiates the patent challenge process under the Hatch-Waxman Act.

The venue of the lawsuit and the attorneys involved were not immediately available.

In October of last year, Spectrum submitted an Abbreviated New Application (ANDA) with the U.S. Food and Drug Administration containing a Paragraph IV...
To view the full article, register now.

Law360 UK

UK Financial Services

Read Our Latest UK Legal News & Analysis

Financial Services Law360 UK and Insurance Law360 UK provide breaking news and in-depth analysis on U.K. and European Union regulation, enforcement, legislation, and litigation involving banks, investment firms, insurers, and more.